Akorn has signed a commercial manufacturing supply agreement with X-Gen Pharmaceuticals for the product, Neomycin and Polymyxin B Sulfates solution for irrigation USP.
X-Gen's Neomycin and Polymyxin B Sulfates solution for irrigation USP was recently approved as an Abbreviated New Drug Application (ANDA) by the FDA. Akorn's Decatur, IL manufacturing facility, with capabilities to produce sterile injectables, ophthalmics, and lyophilized pharmaceuticals, is the approved manufacturing site for this product.
Arthur S. Przybyl, Akorn's president and CEO stated, "Our contract product development and manufacturing business segment is an exciting growth area for the company. Akorn is pleased to be a strategic partner with X-Gen in the manufacturing of this product."
X-Gen president and CEO Susan Badia points out that the introduction of Neomycin and Polymyxin B Sulfates solution for irrigation USP will effectively provide the marketplace with a generic competitor to Neosporin GU Irrigant. She added, "The addition of this product to our offering is another example of X-Gen's long standing tradition and commitment to provide affordable drug therapy options to the healthcare community. We are pleased to have a manufacturing partnership with Akorn as we continue serving the healthcare community as a preferred source for generic choices, including Neomycin and Polymyxin B Sulfates Solution for Irrigation USP."